Drugs / Zymosan
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04674306 | Oct 2021 → Dec 2025 | triple-negative breast carcinoma | George T. Budd | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-12-06 | Anixa Biosciences, Inc. | Results Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine anixa.com ↗
Among the doses studied, Dose Level 1 (10 mcg α-lactalbumin/10 mcg zymosan) was determined to be a usable immunologic dose as well as the maximum tolerated dose (MTD). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-12-06 | Anixa Biosciences, Inc. | Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine anixa.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zymosan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04674306 ↗ |